is retatrutide bad Since January 2026, there have been six cases of acute liver toxicity associated with unapproved peptide products labelled in Australia. These toxic effects may be linked to a contaminant in the Comment “curious” and I'll send

The side effect profile for semaglutide is well-documented

For women with polycystic ovary syndrome (PCOS), a condition closely linked to insulin resistance and obesity, GLP-1-based therapies have shown some promise in improving hormonal profiles, reducing androgen levels, and restoring menstrual regularity

Elkind-Hirsch K, Marrioneaux O, Bhushan M, et al

To date, all CVOTs for dipeptidyl peptidase 4 (DPP-4) inhibitors, 4-7 glucagon-like peptide-1 receptor agonists (GLP-1 RAs), 8-13 and sodium-glucose transport protein 2 (SGLT-2) inhibitors 14-16 have documented a lack of increased CV risk (non-inferiority) with the investigational product in patients with T2DM compared to placebo

As of May 2026, retatrutide (LY3437943) is still investigational

For weight management, a patient typically needs a BMI of 30 kg/m or greater, or a BMI of 27 kg/m or greater with at least one weight-related comorbidity such as hypertension or type 2 diabetes , based on FDA-aligned benchmarks described here